Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Spruce Biosciences (SPRB)
NASDAQ:SPRB
Spruce Biosciences (SPRB) Stock Price & Analysis
271 Followers
SPRB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.67 - $5.95
Previous Close$0.74
Volume350.41K
Average Volume (3M)1.36M
Market Cap
$30.50M
Enterprise Value-$46.76M
Total Cash (Recent Filing)$81.15M
Total Debt (Recent Filing)$3.89M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Aug 07, 2024EPS Estimate
-$0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding41,154,799
10 Day Avg. Volume412,880
30 Day Avg. Volume1,356,959
Standard Deviation0.41
R-Squared0.09
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.46
Price to Sales (P/S)15.25
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-4.64
Enterprise Value/Gross Profit-4.63
Enterprise Value/Ebitda1.37
Forecast
1Y Price Target
$2.75Price Target Upside271.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Spruce Biosciences News
PremiumCompany Announcements
Spruce Biosciences Faces Nasdaq Delisting Threat Over Low Stock Prices
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressSpruce remains on track to report data from both CAHmelia-203 and -205 trials of tildacerfont, which could de-risk the more important CAHmelia-204 trial.
Drug EfficacyConfidence in tildacerfont’s potential for success is based on prior Phase 2a data and recent successful data from a similar CRF-1 receptor antagonist.
Treatment ConvenienceSPRB's drug tildacerfont may offer a more convenient treatment option being a once daily dose compared to crinecerfont's twice daily regimen.
Bears Say
Clinical Trial ResultsThe CAHmelia-203 trial missed its primary endpoint due to low compliance and a hard-to-treat population, which affected drug exposure.
Management DecisionsAnalyst downgrades the stock to Market Perform due to concerns over past management's trial design, patient selection, and dose selection, affecting the reliability of CAHmelia-203 data.
Operational ExecutionPoor treatment compliance and potentially incorrect dose level in the CAHmelia-203 study suggest operational shortcomings.
---
Ownership Overview
44.89% Insiders
2.83% Mutual Funds
38.45% Other Institutional Investors
13.84% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $0.67 and its highest was $5.95 in the past 12 months.
What is Spruce Biosciences’s market cap?
Currently, no data Available
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is Aug 07, 2024 which is in 66 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on May 13, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.289 by $0.009.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate is -$0.3.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 41,154,800 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.289. Following the earnings report the stock price went up 2.5%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Among the largest hedge funds holding Spruce Biosciences’s share is Aisling Capital Management LP. It holds Spruce Biosciences’s shares valued at 946K.
---
Spruce Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.75 (271.07% Upside)
$2.75 (271.07% Upside)
Blogger Sentiment
Bullish
SPRB Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.50%
12-Months-Change
Fundamentals
Return on Equity
-53.55%
Trailing 12-Months
Asset Growth
-37.07%
Trailing 12-Months
Company Description
Spruce Biosciences
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
---
SPRB Earnings Call
Q4 2024
0:00 / 0:00
---
SPRB Stock 12 Month Forecast
Average Price Target
$2.75
▲(271.07% Upside)
Technical Analysis
Best Analysts Covering SPRB
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-29.41%
reiterated a buy rating 19 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -29.41% per trade.
---